目次

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL GENOMICS MARKET ESTIMATION, 2024
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 MNM repository analysis
2.2.1.3 Primary research
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 KEY MARKET PARTICIPANTS: INSIGHTS AND STRATEGIC DEVELOPMENTS
3.3 DISRUPTIVE TRENDS SHAPING GENOMICS MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
?

4 PREMIUM INSIGHTS
4.1 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
4.2 NORTH AMERICA: GENOMICS MARKET, BY APPLICATION AND COUNTRY, 2024
4.3 GENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for genomics projects
5.2.1.2 Increasing prevalence of viral and inherited disorders
5.2.1.3 Advancements in NGS platforms
5.2.1.4 Growing applications of genomics
5.2.2 RESTRAINTS
5.2.2.1 High investment costs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing use of genomics in precision medicine
5.2.3.2 Technological advancements in genomics
5.2.4 CHALLENGES
5.2.4.1 Handling large volumes of data sets and their analysis
5.2.4.2 Clinical utility of genomics
5.3 UNMET NEEDS AND WHITE SPACES
5.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
5.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

6 INDUSTRY TRENDS
6.1 PORTER’S FIVE FORCES ANALYSIS
6.1.1 INTENSITY OF COMPETITIVE RIVALRY
6.1.2 BARGAINING POWER OF SUPPLIERS
6.1.3 BARGAINING POWER OF BUYERS
6.1.4 THREAT OF SUBSTITUTES
6.1.5 THREAT OF NEW ENTRANTS
6.2 MACROECONOMIC OUTLOOK
6.2.1 INTRODUCTION
6.2.2 GDP TRENDS AND FORECAST
6.2.3 TRENDS IN GLOBAL GENOMICS INDUSTRY
6.3 VALUE CHAIN ANALYSIS
6.4 ECOSYSTEM ANALYSIS
6.4.1 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
?
6.5 PRICING ANALYSIS
6.5.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY KEY PLAYER,
2022-2024
6.5.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY KEY PLAYER,
2022-2024
6.5.3 AVERAGE SELLING PRICE OF SERVICES, BY KEY PLAYER, 2024
6.5.4 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022-2024
6.6 TRADE ANALYSIS
6.6.1 IMPORT SCENARIO (HS CODE 3822 & 902789)
6.6.2 EXPORT SCENARIO (HS CODE 3822 & 902789)
6.7 KEY CONFERENCES AND EVENTS, 2026
6.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6.9 INVESTMENT AND FUNDING SCENARIO
6.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
6.10 CASE STUDY ANALYSIS
6.11 IMPACT OF 2025 US TARIFFS—GENOMICS MARKET
6.11.1 INTRODUCTION
6.11.2 KEY TARIFF RATES
6.11.3 PRICE IMPACT ANALYSIS
6.11.4 IMPACT ON COUNTRIES/REGIONS
6.11.4.1 US
6.11.4.2 Europe
6.11.4.3 Asia Pacific
6.11.5 IMPACT ON END-USE INDUSTRIES
6.11.5.1 Pharmaceutical & biotechnology companies
6.11.5.2 CROs and academic & research institutes
6.11.5.3 Hospitals, diagnostic laboratories, and clinics

7 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
PATENTS, AND INNOVATIONS
7.1 TECHNOLOGICAL ANALYSIS
7.1.1 KEY EMERGING TECHNOLOGIES
7.1.1.1 Sequencing by synthesis
7.1.1.2 Single-molecule real-time sequencing
7.1.1.3 Nanopore sequencing
7.1.1.4 qPCR
7.1.1.5 dPCR
7.1.1.6 Microarray technology
7.1.2 COMPLEMENTARY TECHNOLOGIES
7.1.2.1 Cytogenetics
7.1.2.2 Synthetic biology
7.1.2.3 Multiomics
7.1.2.4 Single-cell analysis
7.1.3 ADJACENT TECHNOLOGIES
7.1.3.1 Bioinformatics and computational biology
7.1.3.2 Artificial intelligence and machine learning
7.2 TECHNOLOGY/PRODUCT ROADMAP
7.3 PATENT ANALYSIS
7.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR GENOMICS PATENTS, 2014-2024
7.4 FUTURE APPLICATIONS
7.5 IMPACT OF AI/GEN AI ON GENOMICS MARKET
7.5.1 BEST PRACTICES IN GENOMICS WORKFLOW
7.5.2 CASE STUDIES OF AI IMPLEMENTATION IN GENOMICS MARKET
7.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
7.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GENOMICS MARKET

8 SUSTAINABILITY AND REGULATORY LANDSCAPE
8.1 REGIONAL REGULATIONS AND COMPLIANCE
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8.1.2 INDUSTRY STANDARDS
8.2 SUSTAINABILITY INITIATIVES
8.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
9.1 DECISION-MAKING PROCESS
9.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
9.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
9.2.2 KEY BUYING CRITERIA, BY END USER
9.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
9.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9.5 MARKET PROFITABILITY

10 GENOMICS MARKET, BY OFFERING
10.1 INTRODUCTION
10.2 PRODUCTS
10.2.1 ACCELERATION OF HIGH-THROUGHPUT GENOMICS DRIVEN BY PLATFORM INNOVATION AND AUTOMATION IS BOOSTING GROWTH
10.3 SERVICES
10.3.1 RAPID EXPANSION OF GENOMIC SERVICES FUELED BY CLINICAL ADOPTION AND DATA-DRIVEN DECISION SUPPORT
?

11 GENOMICS PRODUCTS MARKET, BY TYPE
11.1 INTRODUCTION
11.2 REAGENTS, KITS, AND CONSUMABLES
11.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE PROPEL DEMAND FOR REAGENTS, KITS, AND CONSUMABLES
11.3 INSTRUMENTS
11.3.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
11.4 BIOINFORMATICS TOOLS
11.4.1 ACCELERATING GENOMIC INSIGHTS THROUGH SCALABLE, AI-ENABLED BIOINFORMATICS PLATFORMS DRIVE MARKET GROWTH

12 GENOMICS PRODUCTS MARKET, BY TECHNOLOGY
12.1 INTRODUCTION
12.2 SEQUENCING
12.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING
TO DRIVE MARKET GROWTH
12.3 PCR
12.3.1 RISING DEMAND FOR BIOMARKER DISCOVERY TO PROPEL MARKET GROWTH
12.4 GENE EDITING
12.4.1 RISING DEMAND FOR NEWER THERAPEUTIC APPROACHES DRIVING GROWTH
12.5 FLOW CYTOMETRY
12.5.1 RISING DEMAND FOR FLOW CYTOMETRY IN AGRIGENOMICS
TO DRIVE MARKET GROWTH
12.6 MICROARRAYS
12.6.1 RISING ADOPTION OF HIGH-THROUGHPUT TECHNOLOGIES
LIMITING MARKET GROWTH
12.7 IN SITU HYBRIDIZATION
12.7.1 INCREASING DEMAND FOR PRECISE GENE EXPRESSION ANALYSIS
DRIVING GROWTH
12.8 OTHER TECHNOLOGIES

13 GENOMICS PRODUCTS MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
13.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
13.3 ACADEMIC & RESEARCH INSTITUTES
13.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
13.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS PROPELS MARKET
13.5 CROS
13.5.1 RISING COLLABORATION BETWEEN PHARMA COMPANIES AND
CROS DRIVING MARKET GROWTH
13.6 OTHER END USERS

14 GENOMICS SERVICES MARKET, BY TYPE
14.1 INTRODUCTION
14.2 GENOMIC PROFILING & SEQUENCING SERVICES
14.2.1 INCREASED ADOPTION OF SEQUENCING TECHNOLOGIES IN CLINICAL ADOPTION TO SUPPORT MARKET GROWTH
14.3 SAMPLE PREPARATION & LIBRARY PREPARATION SERVICES
14.3.1 INCREASED DEMAND FOR ONCOLOGY AND RARE DISEASE DIAGNOSTICS TO DRIVE MARKET GROWTH
14.4 BIOINFORMATICS SERVICES
14.4.1 RISING DEMAND FOR ADVANCED PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH

15 GENOMICS SERVICES MARKET, BY END USER
15.1 INTRODUCTION
15.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
15.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
15.3 ACADEMIC & RESEARCH INSTITUTES
15.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
15.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO DRIVE GROWTH
15.5 OTHER END USERS

16 GENOMICS MARKET, BY APPLICATION
16.1 INTRODUCTION
16.2 DRUG DISCOVERY & DEVELOPMENT
16.2.1 DRUG DISCOVERY & DEVELOPMENT TO BE LARGEST APPLICATION IN GENOMICS MARKET
16.3 DIAGNOSTICS
16.3.1 CANCER DIAGNOSTICS
16.3.1.1 Rising demand for targeted therapies to drive market growth
16.3.2 INFECTIOUS DISEASES
16.3.2.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth
16.3.3 REPRODUCTIVE HEALTH
16.3.3.1 Rising focus on genetic diseases to drive market growth
16.3.4 OTHER DIAGNOSTIC APPLICATIONS
?
16.4 AGRICULTURE & ANIMAL RESEARCH
16.4.1 GENOMICS TO HELP IMPROVE CROP PRODUCTIVITY
16.5 OTHER APPLICATIONS

17 GENOMICS MARKET, BY STUDY TYPE
17.1 INTRODUCTION
17.2 FUNCTIONAL GENOMICS
17.2.1 INCREASED FOCUS ON FUNCTIONAL GENOME STUDIES
TO DRIVE MARKET GROWTH
17.3 BIOMARKER DISCOVERY
17.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH
17.4 PATHWAY ANALYSIS
17.4.1 RISING PREVALENCE OF COMPLEX DISEASES TO AUGMENT MARKET GROWTH
17.5 EPIGENOMICS
17.5.1 RISING INVESTMENTS FOR EPIGENETICS RESEARCH TO BOOST MARKET GROWTH
17.6 OTHER STUDY TYPES

18 GENOMICS MARKET, BY REGION
18.1 INTRODUCTION
18.2 NORTH AMERICA
18.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
18.2.2 US
18.2.2.1 US expected to dominate market in North America
18.2.3 CANADA
18.2.3.1 Increasing government initiatives in genomics research to boost market growth
18.3 EUROPE
18.3.1 EUROPE: MACROECONOMIC OUTLOOK
18.3.2 GERMANY
18.3.2.1 Germany to dominate European genomics market
18.3.3 UK
18.3.3.1 Strategic initiatives and funding for genomics research to support market growth
18.3.4 FRANCE
18.3.4.1 Increasing government investment in genomics research to drive growth
18.3.5 ITALY
18.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
18.3.6 SPAIN
18.3.6.1 Growing focus on advancements in personalized medicine to support market growth
18.3.7 REST OF EUROPE
18.4 ASIA PACIFIC
18.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
18.4.2 CHINA
18.4.2.1 China to dominate Asia Pacific market during forecast period
18.4.3 JAPAN
18.4.3.1 Rising number of collaborations in genomics to drive market
18.4.4 INDIA
18.4.4.1 Government and private initiatives for genomics to propel market
18.4.5 AUSTRALIA
18.4.5.1 Increased genomics research in Australia to support market growth
18.4.6 SOUTH KOREA
18.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
18.4.7 REST OF ASIA PACIFIC
18.5 LATIN AMERICA
18.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
18.5.2 BRAZIL
18.5.2.1 Increased government investments in genomics advancements to drive market in Brazil
18.5.3 MEXICO
18.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
18.5.4 REST OF LATIN AMERICA
18.6 MIDDLE EAST
18.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
18.6.2 GCC COUNTRIES
18.6.2.1 Saudi Arabia
18.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
18.6.2.2 United Arab Emirates
18.6.2.2.1 Growing collaborations to advance genome sequencing to aid market growth in UAE
18.6.2.3 Rest of GCC Countries
18.6.3 REST OF MIDDLE EAST
18.7 AFRICA
18.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET IN AFRICA
18.7.2 AFRICA: MACROECONOMIC OUTLOOK

19 COMPETITIVE LANDSCAPE
19.1 INTRODUCTION
19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOMICS MARKET
?
19.3 REVENUE ANALYSIS, 2020-2024
19.4 MARKET SHARE ANALYSIS, 2024
19.5 BRAND/PRODUCT COMPARISON
19.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
19.6.1 STARS
19.6.2 EMERGING LEADERS
19.6.3 PERVASIVE PLAYERS
19.6.4 PARTICIPANTS
19.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
19.6.5.1 Company footprint
19.6.5.2 Region footprint
19.6.5.3 Product footprint
19.6.5.4 Application footprint
19.6.5.5 Technology footprint
19.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
19.7.1 PROGRESSIVE COMPANIES
19.7.2 RESPONSIVE COMPANIES
19.7.3 DYNAMIC COMPANIES
19.7.4 STARTING BLOCKS
19.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
19.7.5.1 Detailed list of key startups/SMEs
19.7.5.2 Competitive benchmarking of key startups/SMEs
19.8 COMPANY VALUATION & FINANCIAL METRICS
19.8.1 FINANCIAL METRICS
19.8.2 COMPANY VALUATION
19.9 COMPETITIVE SCENARIO
19.9.1 PRODUCT LAUNCHES
19.9.2 DEALS
19.9.3 EXPANSIONS

20 COMPANY PROFILES
20.1 INTRODUCTION
20.2 KEY PLAYERS
20.2.1 THERMO FISHER SCIENTIFIC INC.
20.2.1.1 Business overview
20.2.1.2 Products/Services offered
20.2.1.3 Recent developments
20.2.1.3.1 Product launches and approvals
20.2.1.3.2 Deals
20.2.1.3.3 Expansions
20.2.1.4 MnM view
20.2.1.4.1 Key strengths
20.2.1.4.2 Strategic choices
20.2.1.4.3 Weaknesses and competitive threats
20.2.2 ILLUMINA, INC.
20.2.2.1 Business overview
20.2.2.2 Products/Services offered
20.2.2.3 Recent developments
20.2.2.3.1 Product launches and approvals
20.2.2.3.2 Deals
20.2.2.3.3 Expansions
20.2.2.3.4 Other developments
20.2.2.4 MnM view
20.2.2.4.1 Key strengths
20.2.2.4.2 Strategic choices
20.2.2.4.3 Weaknesses and competitive threats
20.2.3 DANAHER CORPORATION
20.2.3.1 Business overview
20.2.3.2 Products/Services offered
20.2.3.3 Recent developments
20.2.3.3.1 Product launches
20.2.3.3.2 Deals
20.2.3.3.3 Expansions
20.2.3.4 MnM view
20.2.3.4.1 Key strengths
20.2.3.4.2 Strategic choices
20.2.3.4.3 Weaknesses and competitive threats
20.2.4 F. HOFFMANN-LA ROCHE LTD.
20.2.4.1 Business overview
20.2.4.2 Products/Services offered
20.2.4.2.1 Product launches
20.2.4.2.2 Deals
20.2.4.2.3 Other developments
20.2.4.3 MnM view
20.2.4.3.1 Key strengths
20.2.4.3.2 Strategic choices
20.2.4.3.3 Weaknesses and competitive threats
20.2.5 AGILENT TECHNOLOGIES, INC.
20.2.5.1 Business overview
20.2.5.2 Products/Services offered
20.2.5.3 Recent developments
20.2.5.3.1 Product launches
20.2.5.3.2 Deals
20.2.5.3.3 Expansions
20.2.5.4 MnM view
20.2.5.4.1 Key strengths
20.2.5.4.2 Strategic choices
20.2.5.4.3 Weaknesses and competitive threats
20.2.6 QIAGEN
20.2.6.1 Business overview
20.2.6.2 Products/Services offered
20.2.6.3 Recent developments
20.2.6.3.1 Product launches and approvals
20.2.6.3.2 Deals
20.2.6.3.3 Expansions
20.2.7 REVVITY
20.2.7.1 Business overview
20.2.7.2 Products/Services offered
20.2.7.3 Recent developments
20.2.7.3.1 Product launches
20.2.7.3.2 Deals
20.2.7.3.3 Expansions
20.2.8 LABORATORY CORPORATION OF AMERICA HOLDINGS
20.2.8.1 Business overview
20.2.8.2 Services offered
20.2.8.3 Recent developments
20.2.8.3.1 Service launches
20.2.8.3.2 Deals
20.2.8.3.3 Expansions
20.2.9 IQVIA INC.
20.2.9.1 Business overview
20.2.9.2 Services offered
20.2.9.3 Recent developments
20.2.9.3.1 Deals
20.2.10 CHARLES RIVER LABORATORIES
20.2.10.1 Business overview
20.2.10.2 Services offered
20.2.11 BIO-RAD LABORATORIES, INC.
20.2.11.1 Business overview
20.2.11.2 Products/Services offered
20.2.11.3 Recent developments
20.2.11.3.1 Product launches and approvals
20.2.11.3.2 Deals
20.2.12 EUROFINS SCIENTIFIC
20.2.12.1 Business overview
20.2.12.2 Products/Services offered
20.2.12.3 Recent developments
20.2.12.3.1 Product launches
20.2.12.3.2 Deals
20.2.13 PACBIO
20.2.13.1 Business overview
20.2.13.2 Products/Services offered
20.2.13.3 Recent developments
20.2.13.3.1 Product launches
20.2.13.3.2 Deals
20.2.13.3.3 Expansions
20.2.13.3.4 Other developments
20.2.14 OXFORD NANOPORE TECHNOLOGIES PLC.
20.2.14.1 Business overview
20.2.14.2 Products/Services offered
20.2.14.3 Recent developments
20.2.14.3.1 Product launches
20.2.14.3.2 Deals
20.2.14.3.3 Expansions
20.2.15 TAKARA BIO INC.
20.2.15.1 Business overview
20.2.15.2 Products/Services offered
20.2.15.3 Recent developments
20.2.15.3.1 Product launches
20.2.15.3.2 Deals
20.2.16 BGI GROUP
20.2.16.1 Business overview
20.2.16.2 Products/Services offered
20.2.16.3 Recent developments
20.2.16.3.1 Product & service launches and approvals
20.2.16.3.2 Deals
20.2.16.3.3 Other developments
20.2.17 EPPENDORF SE
20.2.17.1 Business overview
20.2.17.2 Products/Services offered
20.2.17.3 Recent developments
20.2.17.3.1 Product launches
20.2.18 MERCK KGAA
20.2.18.1 Business overview
20.2.18.2 Products/Services offered
20.2.18.3 Recent developments
20.2.18.3.1 Deals
20.2.18.3.2 Expansions
20.2.19 BD
20.2.19.1 Business overview
20.2.19.2 Products/Services offered
20.2.19.3 Recent developments
20.2.19.3.1 Product launches and approvals
20.2.19.3.2 Deals
20.2.20 ABBOTT
20.2.20.1 Business overview
20.2.20.2 Products/Services offered
20.2.21 10X GENOMICS
20.2.21.1 Business overview
20.2.21.2 Products/Services offered
20.2.21.3 Recent developments
20.2.21.3.1 Product launches
20.2.22 NEW ENGLAND BIOLABS
20.2.22.1 Business overview
20.2.22.2 Products/Services offered
20.2.22.3 Recent developments
20.2.22.3.1 Product launches
20.2.22.3.2 Deals
20.2.23 PROMEGA CORPORATION
20.2.23.1 Business overview
20.2.23.2 Products/Services offered
20.2.23.3 Recent developments
20.2.23.3.1 Product launches
20.2.23.3.2 Other developments
20.3 OTHER PLAYERS
20.3.1 CREATIVE BIOGENE
20.3.2 NOVOGENE CO., LTD.
20.3.3 HELIX, INC.
20.3.4 PHALANX BIOTECH GROUP
20.3.5 POLARIS GENOMICS
?

21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS